Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.

ABSTRACT:

Importance

Biomarker testing for driver mutations is essential for selecting appropriate non-small cell lung cancer (NSCLC) treatment but is insufficient.

Objective

To investigate the status of biomarker testing and drug therapy for NSCLC in Japan for identifying problems in treatment.

Design, setting, and participants

The REVEAL cohort study included retrospective data collection and prospective follow-up from 29 institutions across Japan. Of 1500 patients diagnosed with advanced or recurrent NSCLC between January 1 and March 18, 2021, 1479 were eligible. Cases recognized at the wrong clinical stage (n = 12), diagnosed outside the study period (n = 6), not treated according to eligibility criteria before recurrence (n = 2), and with deficient consent acquisition proc

SUBMITTER: Sakamoto T 

PROVIDER: S-EPMC10724778 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature